DK1456651T3 - Selvsamlende molekyler - Google Patents

Selvsamlende molekyler

Info

Publication number
DK1456651T3
DK1456651T3 DK02781023T DK02781023T DK1456651T3 DK 1456651 T3 DK1456651 T3 DK 1456651T3 DK 02781023 T DK02781023 T DK 02781023T DK 02781023 T DK02781023 T DK 02781023T DK 1456651 T3 DK1456651 T3 DK 1456651T3
Authority
DK
Denmark
Prior art keywords
self
assembly
target
molecules
single domain
Prior art date
Application number
DK02781023T
Other languages
English (en)
Inventor
Jianbing Zhang
C Roger Mackenzie
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Application granted granted Critical
Publication of DK1456651T3 publication Critical patent/DK1456651T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Electroluminescent Light Sources (AREA)
DK02781023T 2001-11-30 2002-11-29 Selvsamlende molekyler DK1456651T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33409801P 2001-11-30 2001-11-30
PCT/CA2002/001829 WO2003046560A2 (en) 2001-11-30 2002-11-29 Self-assembly molecules

Publications (1)

Publication Number Publication Date
DK1456651T3 true DK1456651T3 (da) 2008-09-01

Family

ID=23305560

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02781023T DK1456651T3 (da) 2001-11-30 2002-11-29 Selvsamlende molekyler

Country Status (14)

Country Link
US (1) US7655412B2 (da)
EP (1) EP1456651B1 (da)
JP (1) JP4471656B2 (da)
CN (1) CN100335900C (da)
AT (1) ATE394673T1 (da)
AU (1) AU2002349228B2 (da)
BR (1) BR0214621A (da)
CA (1) CA2468583C (da)
DE (1) DE60226486D1 (da)
DK (1) DK1456651T3 (da)
ES (1) ES2306794T3 (da)
MX (1) MXPA04005134A (da)
NZ (1) NZ532838A (da)
WO (1) WO2003046560A2 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2005014615A2 (en) * 2003-06-25 2005-02-17 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
US7713923B2 (en) 2003-06-25 2010-05-11 Massachusetts Institute Of Technology Self-assembling peptides incorporating modifications and methods of use thereof
SI1639011T1 (sl) * 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
EP2267028A3 (en) * 2003-06-30 2011-07-27 Domantis Limited Dual specific single domain antibodies (dAb) conjugated to PEG
CA2547034C (en) * 2003-11-28 2014-02-18 National Research Council Of Canada Anticarcinoma antibodies and uses thereof
CA2554054C (en) * 2004-01-20 2013-06-04 Merus B.V. Mixtures of binding proteins
US20090233357A1 (en) * 2005-09-27 2009-09-17 Abedelnasser Abulrob Targeted Delivery of Compounds Using Multimerization Technology
US20120009624A1 (en) * 2006-12-04 2012-01-12 Jens Sommer-Knudsen Protein particles
AU2008255631B2 (en) * 2007-05-30 2012-07-05 Innovative Purification Technologies Pty Ltd Fluorescent protein particles
EP2692736B1 (en) 2008-10-14 2018-04-18 National Research Council Of Canada Bsa-specific antibodies
CA2740561C (en) 2008-10-14 2021-01-19 National Research Council Of Canada Bsa-specific antibodies
JP2012505893A (ja) * 2008-10-14 2012-03-08 ダウ アグロサイエンシィズ エルエルシー 粘膜送達ペンタボディ複合体（ｍｄｐｃ）による粘膜免疫応答の誘導
CA2744384A1 (en) * 2008-11-26 2010-06-03 National Chung Cheng University Nanoaggregate embedded beads conjugated to single domain antibodies
CN101830986A (zh) * 2009-03-13 2010-09-15 北京表源生物技术有限公司 一种融合蛋白多聚体
WO2010102518A1 (zh) * 2009-03-13 2010-09-16 北京表源生物技术有限公司 一种融合蛋白多聚体
US20100247529A1 (en) * 2009-03-20 2010-09-30 William Patterson Cooperative and dynamic assembly of affinity complexes
EP2563816B1 (en) 2010-04-27 2014-11-12 National Research Council of Canada Anti-icam-1 single domain antibody and uses thereof
US9066986B2 (en) 2010-10-01 2015-06-30 National Research Council Of Canada Anti-CEACAM6 antibodies and uses thereof
CA2815888C (en) 2010-10-25 2020-06-30 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
EA201391086A1 (ru) 2011-01-28 2014-01-30 Нэшнл Рисеч Каунсил Оф Канада Конструирование иммуноглобулиновых доменов
DK3150632T3 (da) 2011-06-10 2020-04-27 Canada Minister Nat Defence Anti-ricin-antistoffer og anvendelser deraf
EP2794661B1 (en) 2011-12-20 2019-03-06 Adaerata, Limited Partnership Single domain antibodies as inhibitors of pcsk9
NZ630568A (en) 2012-04-20 2017-06-30 Merus Nv Methods and means for the production of ch3 domain-comprising molecules
WO2014063253A1 (en) 2012-10-24 2014-05-01 National Research Council Of Canada Anti-campylobacter jejuni antibodies and uses therefor
CA2941654C (en) 2014-03-06 2023-08-08 National Research Council Of Canada Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
EP3114142B1 (en) 2014-03-06 2019-06-05 National Research Council of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
JP6541237B2 (ja) 2014-03-06 2019-07-10 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子１受容体特異的抗体及びそれらの使用
CN104004093B (zh) * 2014-06-03 2017-01-18 大连理工大学 一种抗人甲状旁腺激素的纳米抗体及其筛选方法和应用
WO2016043577A1 (en) 2014-09-16 2016-03-24 Academisch Medisch Centrum Ig-like molecules binding to bmp4
US10098973B2 (en) 2014-10-10 2018-10-16 National Research Council Of Canada Anti-tau antibody and uses thereof
EP4019552A1 (en) 2015-06-10 2022-06-29 National Research Council of Canada Carbonic anhydrase ix-specific antibodies and uses thereof
BR112019000220A2 (pt) 2016-07-06 2019-04-24 National Research Council Of Canada anticorpos humanizados que transmigram a barreira hematoencefálica e usos dos mesmos
US10906973B2 (en) 2016-12-12 2021-02-02 National Research Council Of Canada Antibody variants transmigrating the blood-brain barrier and uses thereof
EP3574008B1 (en) 2017-01-27 2023-11-08 National Research Council of Canada Hemagglutinin-specific antibodies and uses thereof
EP3574002A4 (en) 2017-01-30 2021-04-21 National Research Council of Canada BLOOD ENCEPHALIC BARRIER MIGRATION AGENTS AND ASSOCIATED USES
WO2020086793A1 (en) * 2018-10-25 2020-04-30 Hao Shen Self-assembling protein homo-polymers
CN114099701B (zh) * 2021-11-29 2023-11-10 华中科技大学同济医学院附属协和医院 一种自组装复合多肽及其制备方法和药物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5955293A (en) * 1989-10-17 1999-09-21 New England Medical Center Hospitals, Inc. Assays for shiga toxin and shiga-like toxins
AU690528B2 (en) * 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5744346A (en) * 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
WO1997033617A1 (en) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
EP0923738A1 (en) * 1996-06-11 1999-06-23 Advanced Research & Technology Institute Methods and compositions for the use of apurinic/apyrimidinic endonucleases
WO1998018943A1 (en) * 1996-10-28 1998-05-07 Novartis Ag Method for the oligomerisation of peptides
EP0981369B1 (en) * 1997-05-12 2004-11-17 Aphton Corporation Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors
ES2245052T3 (es) * 1997-12-01 2005-12-16 Fang Fang Anticuerpos de recombinacion multivalentes destinados para el tratamiento de infecciones debidas al rinovirus humano (hrv).
US6310043B1 (en) * 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
MXPA01007602A (es) * 1999-02-01 2003-06-24 Beth Israel Hospital Comp/tsp-1, comp/tsp-2 y otras proteinas quimericas..
AU3798500A (en) * 1999-04-09 2000-11-14 Hsc Research And Development Limited Partnership Verotoxin treatment of lymphomas
NZ518342A (en) 1999-10-08 2004-04-30 Active Biotech Ab AB5 toxin B subunit mutants with altered chemical conjugation characteristics
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
AU2001227966A1 (en) * 2000-01-20 2001-07-31 Chiron Corporation Methods for treating tumors

Also Published As

Publication number Publication date
MXPA04005134A (es) 2004-08-11
WO2003046560B1 (en) 2003-10-16
AU2002349228A1 (en) 2003-06-10
CA2468583C (en) 2012-05-01
US7655412B2 (en) 2010-02-02
ES2306794T3 (es) 2008-11-16
CN100335900C (zh) 2007-09-05
BR0214621A (pt) 2004-10-13
US20060051292A1 (en) 2006-03-09
JP4471656B2 (ja) 2010-06-02
JP2005510719A (ja) 2005-04-21
EP1456651B1 (en) 2008-05-07
WO2003046560A2 (en) 2003-06-05
AU2002349228B2 (en) 2007-06-14
WO2003046560A3 (en) 2003-09-04
DE60226486D1 (de) 2008-06-19
EP1456651A2 (en) 2004-09-15
CA2468583A1 (en) 2003-06-05
ATE394673T1 (de) 2008-05-15
NZ532838A (en) 2008-05-30
CN1596371A (zh) 2005-03-16

Similar Documents

Publication Publication Date Title
DK1456651T3 (da) Selvsamlende molekyler
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
EA201100527A1 (ru) Биологические продукты
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
DE602006013029D1 (de) Anti-egfr-antikörper
MA43028B1 (fr) Anticorps bispécifiques pour pd1 et tim3
MA33213B1 (fr) Anticorps antagoniste specifique d'un heterodimere alpha-4-beta-7
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
ATE513563T1 (de) Therapeutische und toleranz-induzierende antikörper
DE60327205D1 (de) Therapeutische antiköper mit reduzierten nebenwirkungen
EA200800812A1 (ru) Композиции антитела против cd3
WO2009088805A3 (en) Antibody targeting through a modular recognition domain
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
CR10563A (es) Anticuerpos monoclonales ant-il-6 y usos de los mismos
EA200400510A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
RS52775B (en) CD19 OPTIMIZED ANTIBODY
WO2008060367A3 (en) Human antibodies that bind cxcr4 and uses thereof
RS52769B (sr) Kompozicije i postupci za povećanje mineralizacije kostiju
NZ587230A (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
EA200701452A1 (ru) Моноклональные антитела против подобного ангиопоэтину белка 4 (angptl 4)
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
NO932672L (no) Monokloane antistoffer mot elam-1 og anvendelser derav